HARROW, INC. 8-K

What Happened

• Harrow, Inc. filed a Form 8-K on February 2, 2026 announcing two material items: (1) the company reaffirmed its full-year 2025 revenue guidance of $270 million to $280 million in a press release, and (2) on January 30, 2026 the company appointed Patrick W. Sullivan (age 50) as Chief Commercial Officer, effective immediately. Mr. Sullivan joined Harrow as Head of Commercial in August 2025 and brings over 25 years of commercial leadership experience at companies including Corium Therapeutics, AstraZeneca, Shire, Novartis, and Bayer.

Key Details

• 2025 revenue guidance: reaffirmed at $270 million–$280 million (press release furnished Feb 2, 2026).
• New CCO: Patrick W. Sullivan appointed effective Jan 30, 2026; previously Head of Commercial since Aug 2025.
• Compensation (Offer Letter dated Jan 30, 2026):
  • Base salary: $425,000 per year.
  • Target annual bonus: 40% of base pay, subject to agreed targets.
  • Equity: 40,000 restricted stock units (RSUs) — 25,000 RSUs vest upon Harrow achieving $230,000,000 revenue in a calendar quarter; 15,000 RSUs vest after three years.
• No family relationships or related-party transactions requiring disclosure; no other arrangements reported concerning his selection.

Why It Matters

• The reaffirmed $270M–$280M 2025 revenue guidance gives investors clarity on near-term top-line expectations.
• Hiring a seasoned commercial leader with a compensation package tied partly to revenue milestones signals management’s focus on accelerating commercialization and aligning executive pay with revenue performance.
• The RSU vesting tied to a high quarterly revenue threshold highlights a performance-linked incentive that could dilute equity if milestones are met but also indicates management’s emphasis on substantial revenue growth before major equity vesting.